1005 related articles for article (PubMed ID: 34924562)
1. Signal pathways of melanoma and targeted therapy.
Guo W; Wang H; Li C
Signal Transduct Target Ther; 2021 Dec; 6(1):424. PubMed ID: 34924562
[TBL] [Abstract][Full Text] [Related]
2. Molecular pathogenesis of cutaneous melanocytic neoplasms.
Ibrahim N; Haluska FG
Annu Rev Pathol; 2009; 4():551-79. PubMed ID: 19400696
[TBL] [Abstract][Full Text] [Related]
3. Recent discoveries in the genetics of melanoma and their therapeutic implications.
Marquette A; Bagot M; Bensussan A; Dumaz N
Arch Immunol Ther Exp (Warsz); 2007; 55(6):363-72. PubMed ID: 18060370
[TBL] [Abstract][Full Text] [Related]
4. Malignant Melanoma: Autoimmunity and Supracellular Messaging as New Therapeutic Approaches.
Motofei IG
Curr Treat Options Oncol; 2019 May; 20(6):45. PubMed ID: 31056729
[TBL] [Abstract][Full Text] [Related]
5. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas.
Hoek K; Rimm DL; Williams KR; Zhao H; Ariyan S; Lin A; Kluger HM; Berger AJ; Cheng E; Trombetta ES; Wu T; Niinobe M; Yoshikawa K; Hannigan GE; Halaban R
Cancer Res; 2004 Aug; 64(15):5270-82. PubMed ID: 15289333
[TBL] [Abstract][Full Text] [Related]
6. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
7. Focus on melanoma.
Houghton AN; Polsky D
Cancer Cell; 2002 Oct; 2(4):275-8. PubMed ID: 12398891
[No Abstract] [Full Text] [Related]
8. New drug targets in metastatic melanoma.
Homet B; Ribas A
J Pathol; 2014 Jan; 232(2):134-41. PubMed ID: 24027077
[TBL] [Abstract][Full Text] [Related]
9. Metabolic rewiring directs melanoma immunology.
Sun N; Tian Y; Chen Y; Guo W; Li C
Front Immunol; 2022; 13():909580. PubMed ID: 36003368
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Advances and Treatment Options in Metastatic Melanoma.
Johnson DB; Sosman JA
JAMA Oncol; 2015 Jun; 1(3):380-6. PubMed ID: 26181188
[TBL] [Abstract][Full Text] [Related]
11. Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma.
Yu C; Liu X; Yang J; Zhang M; Jin H; Ma X; Shi H
Front Immunol; 2019; 10():990. PubMed ID: 31134073
[TBL] [Abstract][Full Text] [Related]
12. The AP-1 transcription factor FOSL1 causes melanocyte reprogramming and transformation.
Maurus K; Hufnagel A; Geiger F; Graf S; Berking C; Heinemann A; Paschen A; Kneitz S; Stigloher C; Geissinger E; Otto C; Bosserhoff A; Schartl M; Meierjohann S
Oncogene; 2017 Sep; 36(36):5110-5121. PubMed ID: 28481878
[TBL] [Abstract][Full Text] [Related]
13. Canonical Signaling Pathways in Melanoma.
Sun L; Arbesman J
Clin Plast Surg; 2021 Oct; 48(4):551-560. PubMed ID: 34503716
[TBL] [Abstract][Full Text] [Related]
14. Malignant melanoma: evolving practice management in an era of increasingly effective systemic therapies.
Newcomer K; Robbins KJ; Perone J; Hinojosa FL; Chen D; Jones S; Kaufman CK; Weiser R; Fields RC; Tyler DS
Curr Probl Surg; 2022 Jan; 59(1):101030. PubMed ID: 35033317
[No Abstract] [Full Text] [Related]
15. Molecular pathogenesis of sporadic melanoma and melanoma-initiating cells.
Kong Y; Kumar SM; Xu X
Arch Pathol Lab Med; 2010 Dec; 134(12):1740-9. PubMed ID: 21128770
[TBL] [Abstract][Full Text] [Related]
16. NRAS mutant melanoma: Towards better therapies.
Randic T; Kozar I; Margue C; Utikal J; Kreis S
Cancer Treat Rev; 2021 Sep; 99():102238. PubMed ID: 34098219
[TBL] [Abstract][Full Text] [Related]
17. MITF pathway mutations in melanoma.
Yokoyama S; Salma N; Fisher DE
Pigment Cell Melanoma Res; 2009 Aug; 22(4):376-7. PubMed ID: 19558635
[No Abstract] [Full Text] [Related]
18. Stem cells in melanoma development.
Sabatino M; Stroncek DF; Klein H; Marincola FM; Wang E
Cancer Lett; 2009 Jul; 279(2):119-25. PubMed ID: 19095348
[TBL] [Abstract][Full Text] [Related]
19. Management of Acral and Mucosal Melanoma: Medical Oncology Perspective.
Jung S; Johnson DB
Oncologist; 2022 Aug; 27(8):703-710. PubMed ID: 35640549
[TBL] [Abstract][Full Text] [Related]
20. Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.
Vella LJ; Andrews MC; Behren A; Cebon J; Woods K
Expert Rev Clin Immunol; 2014 Aug; 10(8):1107-23. PubMed ID: 24939732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
